Phase 1 Drug Manufacturing: Exempt From Part 211, Not From CGMP

At a glance

• Phase 1 investigational drugs are exempt from 21 CFR part 211. They are not exempt from CGMP, which is required by statute.
• Those are two different things, and collapsing them is the most consequential misreading in early-phase manufacturing.
• The exemption lapses. Once the drug has been made available in a phase 2 or phase 3 study, or lawfully marketed, phase 1 use of it must comply with part 211.
• What FDA expects instead is set out in guidance: quality control functions in place, materials traceable from receipt to use in each batch, procedures scientifically sound for that specific product.
• The guidance is explicitly nonbinding, which changes how you justify decisions rather than whether you have to.

Three layers, routinely collapsed into one

Ask whether CGMP applies to a phase 1 investigational drug and you will get two confident, opposite answers. Both are wrong, because the situation has three layers rather than two.

The statute. Current good manufacturing practice is required under section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act in the manufacture of most investigational new drugs used in phase 1 clinical trials (FDA, CGMP for Phase 1 Investigational Drugs, 2008). This is the obligation, and it does not go away.

The regulations. Those drugs, which include biological drugs, are exempt from complying with 21 CFR part 211 under 21 CFR 210 (FDA, CGMP for Phase 1 Investigational Drugs, 2008). Part 211 is the detailed commercial-manufacturing rulebook, and it does not apply here.

The guidance. With the rulebook removed and the statutory duty standing, FDA published what it expects in between. That document applies quality control principles to the manufacture of phase 1 investigational drugs.

Read the three together and the position is coherent. You still owe CGMP. You do not owe part 211’s specific provisions. What you do owe is an approach appropriate to the stage, and FDA has described one.

The error that costs money runs in both directions. Teams that read “exempt” as “CGMP does not apply” build no quality system and cannot answer for their material. Teams that miss the exemption build full commercial part 211 compliance for a single batch of a first-in-human product, which is expensive and was never required.

The exemption is narrower than its reputation

The exemption lives in Part 210 rather than in Part 211, which is itself a clue: it is a scoping provision, not a relaxation of standards.

More importantly, it is conditional, and the condition is the part most summaries drop. Part 211 does not apply to an investigational drug for use in a phase 1 study once the investigational drug has been made available for use by or for the sponsor in a phase 2 or phase 3 study, or the drug has been lawfully marketed. If the investigational drug has been made available in a phase 2 or phase 3 study, or has been lawfully marketed, the drug for use in the phase 1 study must comply with part 211 (21 CFR §210.2).

Read that carefully, because the practical consequence is counterintuitive.

The exemption is not a property of the trial. It is a property of the product’s development state. A phase 1 study running on a product that has since progressed into phase 2, or that is marketed for another indication, is not covered by the exemption, even though it is unambiguously a phase 1 study.

This matters most in two common situations. A compound that moves forward while an earlier phase 1 cohort is still running. And a marketed product being investigated for a new indication, where the phase 1 framing is accurate clinically and irrelevant to the manufacturing question.

Teams plan for the exemption. They rarely plan for its expiry, and expiry is not announced by anything in the trial.

What changes if the exemption lapses

Because the lapse is easy to miss and expensive to discover late, it is worth knowing concretely what comes back into scope.

Part 211 requires a formally constituted quality unit: there shall be a quality control unit that has the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging material, labeling, and drug products (21 CFR §211.22). That is a defined organisational function with release authority, which is a step beyond the QC functions the phase 1 guidance describes.

It also requires the production controls in full: there shall be written procedures for production and process control designed to assure that the drug products have the identity, strength, quality and purity they purport or are represented to possess (21 CFR §211.100).

Neither is unreasonable for a product heading to market. Both are a materially larger undertaking than a phase 1 operation typically has in place, and neither can be assembled retrospectively for material already manufactured. A sponsor whose compound is progressing should be planning that transition while the exemption still applies, not at the point it stops.

What actually satisfies CGMP at this stage

With part 211 out of scope, the question becomes what a defensible phase 1 manufacturing approach looks like. The guidance is specific enough to work from.

Quality control functions in place. The guidance applies quality control principles to phase 1 manufacture and expects QC functions to exist. Not a quality unit in the part 211 sense, but an identifiable function separate from the people making the material.

Traceability of materials. The manufacturer should be able to identify and trace all materials used in the manufacture of a phase 1 investigational drug from receipt to use in the manufacture of each batch (FDA, CGMP for Phase 1 Investigational Drugs, 2008). Receipt to use, per batch. This is the requirement most small manufacturers underestimate, and it is the one that becomes unrecoverable later, because material provenance cannot be reconstructed after the fact.

Procedures grounded in the actual product. Methods should be based on scientific knowledge and experience for use in the specific phase 1 investigational drug (FDA, CGMP for Phase 1 Investigational Drugs, 2008). Borrowed SOPs from a different molecule do not satisfy this simply by existing.

The organising idea is that phase 1 CGMP is proportionate rather than reduced. The obligations that protect participants and preserve the meaning of the data stay. The obligations that exist to control consistent commercial-scale production do not yet apply.

The nonbinding caveat, handled honestly

The guidance states that its contents should be viewed only as recommendations unless specific regulatory or statutory requirements are cited (FDA, CGMP for Phase 1 Investigational Drugs, 2008).

It is worth being precise about what that does and does not mean.

It does not mean the recommendations are optional in effect. The statutory CGMP obligation under 501(a)(2)(B) is binding, and the guidance is FDA’s description of how to meet it at this stage. Departing from it is permitted; departing from it without an articulated alternative that also meets the statute is not.

What the caveat genuinely gives you is latitude in method. A manufacturer who can explain why a different control achieves the same assurance for this product is in a defensible position. A manufacturer who simply did less, and whose justification is that the guidance is nonbinding, is not.

In practice this shifts the burden from following a rulebook to documenting reasoning, which is the same shift proportionality produces everywhere else in this area.

Where manufacturing meets the trial

The manufacturing question and the trial-conduct question meet at the point of supply, and the handover is cleaner if both sides know where the line falls.

Once product reaches the site, responsibility for investigational product management, including accountability, handling, dispensing, administration and return, rests with the investigator and institution, though the sponsor may facilitate aspects of it (ICH E6(R3) §2.10.1).

So the CGMP discussion above governs how the material was made and released. GCP governs what happens to it afterwards. A phase 1 trial needs both, and gaps tend to appear exactly at the boundary, where each side assumes the other holds a control.

The practical version for a sponsor: know who released the batch and against what, and know who at the site is accountable for it from delivery onward. Those are two different people answering two different regulatory questions about the same vial.

The short version

Phase 1 manufacturing is not a CGMP holiday. It is CGMP without part 211, which means the obligation is intact and the method is yours to determine and defend.

Check three things before relying on the exemption. Is CGMP being met in substance, not just in name. Is the material traceable from receipt through each batch. And has the product moved into phase 2, phase 3 or the market, in which case the exemption has already lapsed and part 211 applies to the phase 1 use as well.

The third is the one that catches people, because nothing in the phase 1 study changes when it happens.

Sources

• FDA Guidance for Industry: CGMP for Phase 1 Investigational Drugs (July 2008)
• 21 CFR Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs: General
• 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals
• ICH E6(R3) Good Clinical Practice, version R3